Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
In experimental stroke models pretreatment with the newly introduced antidiabetic agents, glucagon‐like peptide 1 receptor (GLP‐1R) agonists, has been shown to exert neuroprotective effects. Published evidence with regard to the effect of treatment with GLP‐1R agonists on the risk of stroke was evaluated. Data from prospective randomized placebo‐controlled trials up to October 2018 involving GLP‐1R agonists which reported cardiovascular outcomes as primary end‐points of efficacy and/or safety were meta‐analysed. Five eligible multicentre randomized placebo‐controlled trials (ELIXA, LEADER, SUSTAIN, EXSCEL and HARMONY) were included. The pooled analysis (n = 42 358) showed a significant reduction by 13% in the risk of total stroke from treatment with GLP‐1R agonists versus placebo (risk ratio 0.87, 95% confidence interval 0.78–0.98, P = 0.021) with no significant heterogeneity between trials (Q = 4.094, P = 0.393, I2 = 2.307%). When only fatal stroke was included (this applied for the ELIXA, LEADER, EXSCEL and HARMONY trials), active treatment was associated with a non‐significant reduction by 16% compared with placebo (risk ratio 0.84, 95% confidence interval 0.60–1.17, P = 0.29). The findings of this meta‐analysis support the evidence from earlier experimental studies calling attention to potential ‘stroke protective’ effects from treatment with GLP‐1R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 7×
“The EXSCEL and LEADER trials recruited greater numbers of participants and had the longest follow-up duration periods compared to the other trials [15,16].”
BackgroundResultInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“Cochran’s Q test and I-squared (I(2)) were used to detect any heterogeneity between studies [12,13].”
MethodA Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569 · cited 1×
“Cochran’s Q test and I-squared (I(2)) were used to detect any heterogeneity between studies [12,13].”
MethodLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 6×
“A meta-analysis of 33 trials (n = 15 398) showed no significant effect of GLP-1R agonists against stroke (OR 0.87, 95% CI 0.37–2.05, Table 1 Characteristics of the trials included in the meta-analysis ELIXA LEADER SUSTAIN-6 EXSCEL HARMONY NCT NCT01147250 NCT01179048 NCT01720446 NCT01144338 NCT02465515 Drug Lixisenatid…”
BackgroundResultInfluentialHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Demographic and epidemiologic drivers of global cardiovascular mortality
Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., Naghavi, M., Mensah, G. A., & Murray, C. J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406656 · Cited by 1,188 · cited 4×
“Cardiovascular morbidity and mortality in the developed countries has been shown to decrease during the last decade with effective antihypertensive and lipidlowering therapy taking most of the credit [1].”
BackgroundInfluentialPioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124 · cited 1×
“Indeed, two trials involving stroke patients with T2DM and patients with insulin resistance showed that treatment with pioglitazone was associated with a reduction in the risk of recurrent stroke [8,9].”
BackgroundGLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104 · cited 1×
“Given the positive effect of GLP-1R agonists on weight gain, blood pressure and serum lipids along with the beneficial results of the experimental studies, trials with these agents were awaited with the expectation of proving their neuroprotective effect against stroke in clinical practice [19].”
Background
Research works printed but not linked: 15
- 10.1002/dmrr.568 · DOI · Paper page
- 10.1016/S1474-4422(12)70005-4 · DOI · Paper page
- 10.1038/jcbfm.2015.17 · DOI · Paper page
- 10.1007/s11154-014-9285-9 · DOI
- 10.1016/S2213-8587(13)70125-6 · DOI
- 10.1161/01.STR.0000257974.06317.49 · DOI · Paper page
- 10.1016/j.diabet.2016.10.006 · DOI
- 10.1056/NEJMoa1612917 · DOI · Paper page
- 10.2337/dc15-2145 · DOI · Paper page
- 10.2337/dc10-1393 · DOI · Paper page
- 10.1111/dom.12175 · DOI · Paper page
- 10.1001/jama.2016.9400 · DOI · Paper page
- 10.1016/j.ijcard.2017.03.163 · DOI
- 10.2174/1573399813666170414101450 · DOI
- 10.1177/1747493018784436 · DOI
Cited by
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Our findings are relevant beyond AD and PD, because systemically administered IRAs also show promise in treating other neurological conditions, most notably amyotrophic lateral sclerosis (ALS) [133, 134], stroke [100, 135-140], and traumatic brain injury (TBI) [141].”
BackgroundThe effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30423-1 · Cited by 137
Metadata
- Authors
- Barkas, F., Elisaf, M., & Milionis, H.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2019-01-30
- Volume
- 26
- Issue
- 4
- Pages
- 559-565
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2908687677
- Cited by
- 43
- References
- 10
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/ene.13905
- The paper
- Barkas, F., Elisaf, M., & Milionis, H. (2019). Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis. European Journal of Neurology. https://doi.org/10.1111/ene.13905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.